GTC Biotherapeutics (fka GTCB)

[gym gravity]

"I don't know if there have been any sales of ATryn, has there?"

in the last cc transcript:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29148987

During this second quarter, we anticipate in excess of $7 million in cash receipts from our external programs and from the sale of product to LEO, which was manufactured in Q4 and Q1. This should significantly reduce the net cash used in the second quarter. We project the net cash use for the remainder of 2008 in the range of $17 million to $19 million, which is consistent with our previous guidance [#msg-29133935]. Importantly, any upfront payments from new partnering agreements would further reduce the net cash use forecasted for 2008.